在美国,使用一种或多种双特异性抗体用于扩散性大B细胞淋巴瘤和卵泡淋巴瘤的操作效率
Tara Graff1, Savreet Bains Chawla2, Monika Jun2
1Hematology/Oncology, Mission Cancer + Blood, Des Moines, IA, USA.
Future oncology (London, England)
|February 27, 2026
概括
使用单个双特异性抗体 (bsAb) 治疗复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 和卵泡性淋巴瘤 (FL) 对美国瘤实践相比单独治疗,可以大大节省时间和成本.
科学领域:
- 在瘤学瘤学.
- 药物经济学 药物经济学
- 血液学 血液学 血液学
背景情况:
- 复发性/耐药性 (R/R) 扩散性大B细胞淋巴瘤 (DLBCL) 和毛囊性淋巴瘤 (FL) 经常用单独的疗法治疗.
- 双特异性抗体 (bsAbs) 为简化治疗方法提供了潜力.
研究的目的:
- 量化美国瘤实践的时间和成本节省,使用单个bsAb用于R/RDLBCL和FL,而不是两个单独的单一指示疗法.
- 评估通过采用 bsAb 获得的运营效率的影响.
主要方法:
- 在美国对105名临床医生 (瘤学家,药剂师,护士/医生助理) 进行的一项全国性调查,他们治疗非霍奇金淋巴瘤 (NHL).
- 量化分析根据调查数据和假设的患者访问频率估计节省了时间.
- 节省成本是通过将时间节省与员工工资率相结合来计算的.
主要成果:
- 运营效率的提高是由登机,保险协调和药物准备推动的.
- 对于一个假设的社区实践,治疗100名符合条件的患者,第一年的时间节省为3110小时,相当于278,013美元.
- 一个假设的学术实践实现了第一年的货币化时间节省963,074.4美元.
结论:
- 预计R/R DLBCL和FL的单个bsAb将为瘤实践带来大量的时间和成本节省.
- 通过单个 bsAb 简化治疗,可以提高运营效率并降低医疗保健支出.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
311
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
311
Bioequivalence of Drugs: Drugs with Multiple Indications
197
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
197
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K


